Vicasol pills 15 mg, 20 pcs.

Composition

Active ingredient:

15 mg of menadione sodium bisulfite.

Pharmacological action

Vikasol is a synthetic water-soluble analog of vitamin K (vitamin K3), promotes the synthesis of prothrombin and proconvertin, increases blood clotting by enhancing the synthesis of II, VII, IX, X coagulation factors.

It has a hemostatic effect (if vitamin K is deficient, increased bleeding occurs).

In the blood, prothrombin (factor II) in the presence of thromboplastin and calcium, with the participation of proconvertin (factor VII), factors IX (Christmas factor), X (Stewart-Prauer factor) passes into thrombin, under the influence of which fibrinogen turns into fibrin, which forms the basis of a blood clot (thrombus).

The substrate stimulates K-vitamin reductase, which activates vitamin K and ensures its participation in the hepatic synthesis of K-vitamin-dependent plasma hemostatic factors.

The effect starts in 8-24 hours.

Pharmacokinetics

After intramuscular administration, it is easily and quickly absorbed. It accumulates in small amounts in the tissues. After undergoing a cycle of metabolic activation, it is oxidized to the diol form.

They are excreted by the kidneys (up to 70%) and with bile exclusively in the form of metabolites.

High concentrations of vitamin K in feces are caused by its synthesis by the intestinal microflora.

Indications

• bleeding after wounds or surgical interventions;
• gastrointestinal bleeding;
• hemorrhoidal and prolonged nosebleeds;
• uterine bleeding;
• pulmonary bleeding on the background of tuberculosis.

Contraindications

• hypersensitivity to the components of the drug;
• increased blood clotting, thromboembolism;
• hemolytic disease of newborns.

With caution: deficiency of-6-phosphate dehydrogenase, hepatic insufficiency.

Side effects

• Allergic reactions: flushing of the face, itchy skin, skin rash, bronchospasm.
• From the blood system: hemolytic anemia, hemolysis in newborns with congenital glucose-6-phosphate dehydrogenase deficiency, hemolytic disease of newborns.
• Local reactions: pain and swelling at the injection site, skin damage in the form of spots with repeated injections in the same place.
• Others: hyperbilirubinemia, jaundice (including nuclear jaundice in infants), dizziness, transient decrease in blood pressure, “profuse” sweat, tachycardia, ” weak ” filling of the pulse, changes in taste sensations.

Interaction

Antacids reduce absorption due to the deposition of bile salts in the initial part of the small intestine.

It does not affect the anticoagulant activity of heparin.

Simultaneous administration with broad-spectrum antibiotics, quinidine, quinine, high-dose salicylates, and antibacterial sulfonamides requires an increase in the dose of vitamin K.

Colestyramine, colestipol, mineral oils, sucralfate, dactinomycin reduce the absorption of vitamin K, which requires an increase in its dose.

Concomitant administration with hemolytic drugs increases the risk of side effects

How to take, course of administration and dosage

Adults Vikasol is prescribed orally at 15-30 mg per day.

Children under the age of 1 year – 2-5 mg per day, from 1 to 2 years-6 mg per day,3-4 years-8 mg per day,5-9 years-10 mg per day,10-14 years-15 mg per day. The frequency of reception is 2-3 times a day.

The maximum daily dose of the drug for newborns is 4 mg.

The duration of treatment is 3-4 days.

The course of treatment is repeated after a 4-day break.

Overdose

Rarely-hypervitaminosis K, manifested by hyperprothrombin and hyperthrombinemia, hyperbilirubinemia, increased blood clotting, thromboembolism. Treatment is symptomatic.

Special instructions

Parenteral administration is recommended for diseases that lead to impaired bile outflow. In hemophilia and Werlhof’s disease, the drug is ineffective.

Reduces the effects of indirect anticoagulants.

For the prevention of hemorrhagic disease of newborns, phytonadion is more preferable than menadione sodium bisulfite, since it less often causes hyperbilirubinemia and hemolytic anemia in newborns (including premature babies).

Influence on the ability to drive motor vehicles and manage mechanisms

During treatment with the drug, you should refrain from driving vehicles and engaging in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Composition

Tablet Form of production

Storage conditions

In a place protected from light, at a temperature not exceeding 25 °C.

Shelf

life is 3 years.

Active ingredient

Menadione Sodium bisulfite

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For Adults, For pregnant women, For children

Indications

Menstrual disorders, Cirrhosis of the liver, Bleeding, Hepatitis

Weight

Weight: 8 gr.